T-cell prolymphocytic leukemia medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
==Medical Therapy== | ==Medical Therapy== | ||
*The mainstay of [[therapy]] for [[T cell|T-cell]] [[prolymphocytic leukemia]], include:<ref name="pmid23382603">{{cite journal |vauthors=Graham RL, Cooper B, Krause JR |title=T-cell prolymphocytic leukemia |journal=Proc (Bayl Univ Med Cent) |volume=26 |issue=1 |pages=19–21 |year=2013 |pmid=23382603 |pmc=3523759 |doi= |url=}}</ref><ref name="pmid17392661">{{cite journal |vauthors=Robak T, Robak P |title=Current treatment options in prolymphocytic leukemia |journal=Med. Sci. Monit. |volume=13 |issue=4 |pages=RA69–80 |date=April 2007 |pmid=17392661 |doi= |url=}}</ref> | *The mainstay of [[therapy]] for [[T cell|T-cell]] [[prolymphocytic leukemia]], include:<ref name="pmid23382603">{{cite journal |vauthors=Graham RL, Cooper B, Krause JR |title=T-cell prolymphocytic leukemia |journal=Proc (Bayl Univ Med Cent) |volume=26 |issue=1 |pages=19–21 |year=2013 |pmid=23382603 |pmc=3523759 |doi= |url=}}</ref><ref name="pmid17392661">{{cite journal |vauthors=Robak T, Robak P |title=Current treatment options in prolymphocytic leukemia |journal=Med. Sci. Monit. |volume=13 |issue=4 |pages=RA69–80 |date=April 2007 |pmid=17392661 |doi= |url=}}</ref> | ||
:*[[Alemtuzumab]] (anti-CD52) | :*[[Alemtuzumab]] (anti-[[CD52]]) | ||
*[[T cell|T-cell]] [[prolymphocytic leukemia]] is often resistant to [[therapy]]. | *[[T cell|T-cell]] [[prolymphocytic leukemia]] is often resistant to [[therapy]]. | ||
Latest revision as of 18:25, 4 April 2019
|
T-cell prolymphocytic leukemia Microchapters |
|
Differentiating T-cell prolymphocytic leukemia historical perspective from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
T-cell prolymphocytic leukemia medical therapy On the Web |
|
American Roentgen Ray Society Images of T-cell prolymphocytic leukemia medical therapy |
|
Risk calculators and risk factors for T-cell prolymphocytic leukemia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Qurrat-ul-ain Abid, M.D.[2], Maria Fernanda Villarreal, M.D. [3] Carlos A Lopez, M.D. [4]
Overview
T-cell prolymphocytic leukemia responds better when combinations of chemotherapy drugs are used. Monoclonal antibodies are a type of biological therapy that has been effective in treating certain types of leukemias. Splenectomy and external beam radiation therapy to the spleen may be used in some people with prolymphocytic leukemia.
Medical Therapy
- The mainstay of therapy for T-cell prolymphocytic leukemia, include:[1][2]
- Alemtuzumab (anti-CD52)
- T-cell prolymphocytic leukemia is often resistant to therapy.
Chemotherapy
T-cell prolymphocytic leukemia responds better when combinations of chemotherapy drugs are used. Some combinations that may be used are:[3]
- CVP – Cyclophosphamide, vincristine and prednisone.
- CHOP – Cyclophosphamide, doxorubicin, vincristine and prednisone.
Other chemotherapy drugs (purine analogues) are often used to treat T-cell prolymphocytic leukemia are:
Biological therapy
Monoclonal antibodies are a type of biological therapy that has been effective in treating certain types of leukemias. These drugs may be used alone or in combination with chemotherapy to treat prolymphocytic leukemia.
- Alemtuzumab seems to be particularly effective in treating T-cell prolymphocytic leukemia. It may be used in people whose lymphoma is no longer responding to chemotherapy drugs like fludarabine.
Splenectomy or radiation therapy to the spleen
Splenectomy and external beam radiation therapy to the spleen may be used in some people with prolymphocytic leukemia.
References
- ↑ Graham RL, Cooper B, Krause JR (2013). "T-cell prolymphocytic leukemia". Proc (Bayl Univ Med Cent). 26 (1): 19–21. PMC 3523759. PMID 23382603.
- ↑ Robak T, Robak P (April 2007). "Current treatment options in prolymphocytic leukemia". Med. Sci. Monit. 13 (4): RA69–80. PMID 17392661.
- ↑ "Canadian Cancer Society".